DOSAGE INDEX / SINGLE
PEG MGF
Research, reported schedules and supply planning.
Assess PEG-MGF identity and half-life claims, related MGF findings, FDA safety concerns and the missing direct evidence for human recovery benefits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 200–500 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8 weeks; source also mentions 12–16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 2 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A rat osteoblast study reported increased proliferation and migration together with inhibited differentiation in experiments involving MGF. It investigated mechanical-stress biology and cell responses, not the clinical performance of an identified PEG-MGF product. [1]
- A separate muscle-cell study failed to reproduce claimed effects of MGF peptides in several experimental systems. Its tested materials and negative findings are relevant context for evaluating broad MGF narratives, but do not supply a direct trial of every PEG-modified preparation. [2]
- FDA identifies potential immunogenicity, peptide-related impurities and active-ingredient characterization as concerns for compounded PEG-MGF preparations. Its resource also states that important human safety information is missing. The agency lists PEG-MGF among nominations that were withdrawn, rather than presenting withdrawal as an approval decision. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 11 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original osteoblast paper
- Original replication study
- FDA resource checked for this review
- Physiological SocietyFurther reading · Listed in reference bibliography.
- In Vivo (PubMed)Further reading · Listed in reference bibliography.
- International Orthopaedics (PubMed)Further reading · Listed in reference bibliography.
- Frontiers in Physiology (PubMed)Further reading · Listed in reference bibliography.
- CureusFurther reading · Listed in reference bibliography.
- Rapid Communications in Mass Spectrometry (PubMed)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- Cleveland ClinicFurther reading · Listed in reference bibliography.
- East Carolina University College of NursingFurther reading · Listed in reference bibliography.
- American Journal of Transplantation (PubMed)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.